Professor Xiaohui Zhang: Building on 25 Years of Progress—Advancing High-Quality Development in Hematologic Immunology

Professor Xiaohui Zhang: Building on 25 Years of Progress—Advancing High-Quality Development in Hematologic Immunology

In March, as spring brings renewed vitality to Beijing, the 9th Beijing Conference on Thrombosis and Hemostasis, together with the 7th Beijing Hematologic Oncology and Immunology Summit Forum, was held from March 27 to 28, 2026, coinciding with the 25th anniversary of the Hematology and Immunology Branch of the Chinese Society of Immunology.
Professor Hongmei Jing: From Nature Breakthroughs to Clinical Practice—Advances in Precision Diagnosis and Treatment of Lymphoma

Professor Hongmei Jing: From Nature Breakthroughs to Clinical Practice—Advances in Precision Diagnosis and Treatment of Lymphoma

In March, as spring brings renewed vitality to Beijing, the 9th Beijing Conference on Thrombosis and Hemostasis, together with the 7th Beijing Hematologic Oncology and Immunology Summit Forum, was held from March 27 to 28, 2026. Centered on advances in the diagnosis and treatment of thrombotic and hemostatic disorders, as well as hematologic malignancies and immunology, the meeting highlighted cutting-edge developments and evolving clinical strategies.
Professor Zonghong Shao：Immune Dysregulation in Myelodysplastic Syndromes and Clinical Management Strategies

Professor Zonghong Shao：Immune Dysregulation in Myelodysplastic Syndromes and Clinical Management Strategies

In March, as spring brings renewed vitality to Beijing, the 9th Beijing Conference on Thrombosis and Hemostasis, together with the 7th Beijing Hematologic Oncology and Immunology Summit Forum, was held from March 27 to 28, 2026. Centered on advances in the diagnosis and treatment of thrombotic and hemostatic disorders, as well as hematologic malignancies and immunology, the meeting highlighted cutting-edge developments and evolving clinical strategies.
Professor Junmin Li: Exploration and Clinical Practice of Umbilical Cord Blood Therapy in Elderly Patients with Acute Myeloid Leukemia

Professor Junmin Li: Exploration and Clinical Practice of Umbilical Cord Blood Therapy in Elderly Patients with Acute Myeloid Leukemia

In March, as spring brings clarity and renewal to Beijing, the 9th Beijing Conference on Thrombosis and Hemostasis, together with the 7th Beijing Hematologic Oncology and Immunology Summit Forum, was convened from March 27 to 28, 2026, marking the 25th anniversary of the Hematology and Immunology Branch of the Chinese Society of Immunology.
Professor Zhenyu Yan: Seven Transformations in the Comprehensive Management of Hemophilia in China — From Survival to Functional Cure

Professor Zhenyu Yan: Seven Transformations in the Comprehensive Management of Hemophilia in China — From Survival to Functional Cure

In March, as spring breathes new life into Beijing, the 9th Beijing Conference on Thrombosis and Hemostasis, organized by the Hematology and Immunology Branch of the Chinese Society of Immunology, together with the 7th Beijing Hematologic Oncology and Immunology Summit Forum, was successfully convened from March 27 to 28, 2026. During the meeting, Professor Zhenyu Yan from the Affiliated Hospital of North China University of Science and Technology delivered a keynote lecture entitled “Seven Transformations in the Comprehensive Diagnosis and Management of Hemophilia in China.”
Professor Gang Zhu: Prevention and Treatment of Urologic Tumors — Early Screening Is Key, Personalized Care Enhances Patient Experience

Professor Gang Zhu: Prevention and Treatment of Urologic Tumors — Early Screening Is Key, Personalized Care Enhances Patient Experience

With the aging population and changes in lifestyle in China, the incidence of urologic cancers has been steadily increasing. Oncology Frontier – UroStream invited Professor Gang Zhu from Beijing United Family Hospital to discuss prevention strategies and personalized medical care in urologic oncology. Drawing from clinical practice, he emphasized the importance of early screening and diagnosis, as well as the unique features of international-standard medical services.
ASCO GU Key Opinion Leaders | Michiel van der Heijden: ADC + Immunotherapy Reshapes Urothelial Carcinoma Treatment, Opening New Paths for Bladder Preservation and Personalized Care

ASCO GU Key Opinion Leaders | Michiel van der Heijden: ADC + Immunotherapy Reshapes Urothelial Carcinoma Treatment, Opening New Paths for Bladder Preservation and Personalized Care

At the 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), one of the world’s most prestigious meetings in genitourinary oncology, multiple landmark studies were presented that are reshaping clinical practice. Among them, advances in urothelial carcinoma (UC) stood out prominently.
ASCO GU Insights | Haige Chen: Breakthroughs in Bladder Cancer and the New Era of Precision Treatment

ASCO GU Insights | Haige Chen: Breakthroughs in Bladder Cancer and the New Era of Precision Treatment

At the 2026 Genitourinary Cancers Symposium of the American Society of Clinical Oncology (ASCO GU 2026), held in San Francisco, leading experts from around the world gathered to present cutting-edge advances in urothelial carcinoma (UC). Key themes included antibody–drug conjugate (ADC) plus immunotherapy strategies for bladder preservation, clinical translation of liquid biopsy technologies, and deeper exploration of tumor molecular mechanisms.